Breakthrough may lead to anti-stroke vaccine

EU-funded scientists have discovered that the presence of low levels of a type of antibody in the immune system increases the chance of having a stroke, one of the leading causes of death worldwide. The finding, published in the journal Stroke, signals hope the development of a vaccine that can activate the body's natural defences against the condition.

The breakthrough is part of CVDIMMUNE (Immunomodulation and autoimmunity in cardiovascular disease and atherosclerosis), a project funded EUR 2.7 million under the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6).

In the past, researchers from Karolinska Institutet in Sweden (the project's coordinating institution) were able to prove that the presence of high levels of an antibody, known as anti-PC, in the human body's immune system reduced the risk of arteriosclerosis. Arteriosclerosis occurs when plaque builds up on blood vessel walls. These plaques can rupture and develop into a blood clot. Atherosclerosis, which is a form of arteriosclerosis, is the most common cause of cardiovascular disease.

In the current study, the CVDIMMUNE team turned their attention to strokes, and discovered a similar outcome; people with low anti-PC levels were at an increased the risk of stroke. Lower levels of these natural antibodies, which could be the result of an unhealthy immune system, can therefore contribute to the onset of both arteriosclerosis and stroke.

The research, which involved a comparison study of 227 first-time stroke victims with 445 controls over a 13-year period (between 1985 and 1999), also demonstrated that the link between low anti-PC levels and stroke risk was particularly strong for women.

The results have opened the door to several possibilities. Measurements of anti-PC could now be used by doctors to identify those who are at greater risk of stroke, such as immunodeficient individuals. Likewise, the potential now exists for novel modes of treatment, such as immunotherapies.

Head of the study, Professor Johan Frostegård, said: "We're now examining the possibility of developing new immunological treatments for arteriosclerosis and stroke, either in the form of a vaccine to stimulate the immune defence or immunisation through the injection of antibodies."

The World Health Organization (WHO) estimates that 15 million people across the world suffer a stroke ever year. One third of these people die, and an additional third are left with some form of permanent disability. High blood pressure is believed to be the main culprit, contributing to almost 13 million of these strokes.

In Europe, the WHO estimates that strokes are responsible, on average, for 650,000 deaths every year. Quit-smoking campaigns and efforts focused on lowering blood pressure have helped reduce the incidence of stroke in developed countries. Due to the advent of an ageing population, however, the threat of stroke remains high in these countries.

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...